Press release
Sanjar Pharma LLP Expands Product Line with Anticoagulant Injections for Healthcare Providers
Sanjar Pharma LLp is taking direct bulk orders from clinics, pharma dealers and distributors.
Heparin (HEP a rin) is a well-known anticoagulant utilized in various medical environments to avert clot formation. It plays a vital role during open-heart surgeries, dialysis treatments, and in managing patients with limited mobility. By effectively preventing clots from forming or growing, Heparin contributes to safer treatment protocols and improves patient outcomes.
Enoxaparin, in contrast, is specifically recommended for preventing blood clots in patients undergoing surgeries like hip and knee replacements or those who are on bed rest. Frequently used alongside aspirin, Enoxaparin helps lower the risk of complications from angina and heart attacks, providing crucial support to patients during their recovery.
Recognizing the critical demand for these medications in healthcare, Sanjar Pharma is reaching out to pharma dealers, distributors, clinics, hospitals, and pharmacies to place bulk orders, starting with a minimum of $400. Committed to excellence, Sanjar Pharma has built a reputation as a reliable partner in the healthcare industry, proudly collaborating with well-known companies like Sun Pharma and Cadila Pharmaceutical Company.
Sanjar Pharma boasts cutting-edge manufacturing facilities that utilize advanced technology and are staffed by skilled professionals dedicated to upholding the highest quality standards. The company follows strict quality control protocols to ensure that all products comply with the rigorous guidelines established by GMP, WHO, ISO, and GLP.
As the demand for safe and effective anticoagulants continues to rise, Sanjar Pharma is well-positioned to fulfill the needs of healthcare providers around the globe. The company encourages interested parties to seize this opportunity to expand their product range and prioritize patient safety.
For inquiries or to place an order, please contact Sanjar Pharma LLP directly.
About Sanjar Pharma LLP:
Sanjar Pharma LLP is a prominent distributor and manufacturer of pharmaceutical products based in Gujarat, India. With a focus on quality and innovation, the company is dedicated to providing healthcare solutions that meet the needs of patients and providers alike.
Contact Us:
Whatsapp us: +916352986603
Call us: 02772-245249
Visit us: https://sanjarpharma.com/
Himatnagar - Vijapur Hwy, Dedhrota, Gujarat
Sanjar Pharma LLP is a prominent distributor and manufacturer of pharmaceutical products based in Gujarat, India. With a focus on quality and innovation, the company is dedicated to providing healthcare solutions that meet the needs of patients and providers alike.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sanjar Pharma LLP Expands Product Line with Anticoagulant Injections for Healthcare Providers here
News-ID: 3703657 • Views: โฆ
More Releases for Heparin
Heparin (Heparin Sodium and Heparin Calcium) Market Size, Overview And Forecast โฆ
"The Global Heparin (Heparin Sodium and Heparin Calcium) Market Size is projected to reach at a CAGR of 3.4% during 2024-2032."
Global Heparin (Heparin Sodium and Heparin Calcium) market Size, Status, and Forecast for the 2024-2032. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Heparin (Heparin Sodium and Heparin Calcium) Market includingโฆ
Heparin (Heparin Sodium and Heparin Calcium) Market explores demand trends, grow โฆ
"๐๐ฆ๐ฉ๐จ๐ฐ๐๐ซ๐ข๐ง๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ๐๐ฌ ๐ฐ๐ข๐ญ๐ก ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐ฏ๐ ๐๐๐ซ๐ค๐๐ญ ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ ๐๐จ๐ซ ๐๐ฆ๐๐ซ๐ญ๐๐ซ ๐๐๐๐ข๐ฌ๐ข๐จ๐ง-๐๐๐ค๐ข๐ง๐ "
The global Heparin (Heparin Sodium and Heparin Calcium) market is anticipated to grow from USD 1,202 Million in 2023 to USD 1,509 Million by 2033, at a CAGR of 3.3 % during the forecast period.
Heparin (Heparin Sodium and Heparin Calcium) ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐, ๐๐๐จ๐ฉ๐, ๐๐ง๐ ๐
๐จ๐ซ๐๐๐๐ฌ๐ญ ๐๐๐๐-๐๐๐๐ ๐ซ๐๐ฉ๐จ๐ซ๐ญ ๐ก๐๐ฌ ๐๐๐๐ง ๐ข๐ง๐๐ฅ๐ฎ๐๐๐ ๐ข๐ง ๐๐ฑ๐๐๐ญ๐ข๐ญ๐ฎ๐๐ ๐๐จ๐ง๐ฌ๐ฎ๐ฅ๐ญ๐๐ง๐๐ฒ'๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฅ๐๐๐ญ๐ข๐จ๐ง.
Heparin (Heparin Sodium and Heparin Calcium) Marketโฆ
Heparin Market Report 2023 | Increasing the Advantages of Low Molecular Weight H โฆ
According to Precision Business Insights (PBI), the latest report the global heparin market size was valued at USD 7,923.7 million in 2022 and is projected to grow at a 2.8% CAGR during the forecast period 2023 to 2029. The efficacy of these drugs as an anticoagulant is one of the key factors expected to drive global market growth. Furthermore, undeniable factors such as technological advancement and introducing of new productsโฆ
Heparin Market
The heparin market refers to the global market for heparin, a blood-thinning medication that is commonly used in the prevention and treatment of blood clots. Heparin is typically derived from the mucous membranes of animals such as pigs and cows, and it is commonly used in a variety of medical settings, including hospitals, clinics, and home care settings.
The heparin market has experienced steady growth over the past few years, drivenโฆ
Global Heparin(Heparin Sodium and Heparin Calcium) Market drivers, restraints, g โฆ
Latest industry research report on: Global Heparin(Heparin Sodium and Heparin Calcium) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
This report studies the global Heparin(Heparin Sodium and Heparin Calcium) market status and forecast, categorizes the global Heparin(Heparin Sodium and Heparin Calcium) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China,โฆ
Heparin Market: Rapid Growth of Heparin Market Anticipated in Several European N โฆ
Europe is among the major regions contributing to the global heparin market owing to its developed economy and high prevalence of coagulation disorders. According to the Ageing Report published by the European Commission in 2015, the percentage of population aged above 65 years is expected to increase from 21.0% in 2013 to 32.0% in 2060. Aging is directly proportional to the rising incidence of venous thromboembolism (VTE) diseases such asโฆ
